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introduction: Concurrent chemoradiotherapy (CCRT) is the standard treatment for 
locally advanced non-small cell lung cancer (LA-NSCLC) but is associated with poor 
chest tumor control. Here, we report results of a randomized phase 3 study comparing 
two CCRT regimens in improving chest tumor control by low-dose paclitaxel chemora-
diation for LA-NSCLC.
Methods: Due to the logistics of local referral pattern, the study was designed to enroll 
patients with stage III LA-NSCLC who had completed 2–4 cycles of full-dose chemo-
therapy. One hundred thirty four were randomized to either Arm 1 [paclitaxel at 15 mg/
m2, three times per week (Monday, Wednesday, and Friday) for 6 weeks, n = 74] or Arm 
2 (weekly paclitaxel at 45 mg/m2 for 6 weeks, n = 60). Chest radiotherapy was 60–70 Gy 
in standard fractionation. Response rate was the primary endpoint, with recurrence-free 
survival (RFS) as the secondary endpoint.
results: From March 2006 to February 2013, 71 patients completed Arm 1 treatment 
and 59 completed Arm 2 treatment. The response rate for Arm 1 was significantly 
higher (83.1%) than Arm 2 (54.2%) (p=0.001). RFS was superior in Arm 1: median 14.6 
vs. 9.4 months, p = 0.005, Hazard ratio (HR) 1.87 [95% confidence interval (CI) 1.20, 
2.90]. Overall survival was not significantly different: median 32.6 months in Arm 1 vs. 
31.3 months in Arm 2, p = 0.91, HR 0.97 (95% CI 0.55, 1.70). Toxicity was significantly 
lower in Arm 1 for Grade 3 and 4 leukopenia/neutropenia (p < 0.001).
Conclusion: Pulsed low-dose paclitaxel CCRT resulted in significantly better RFS and 
tumor response rate, and less hematologic toxicities than weekly CCRT for LA-NSCLC.
Keywords: non-small cell lung cancer, paclitaxel, chemoradiotherapy, radiosensitization, phase 3 trial
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inTrODUCTiOn
Lung cancer is the leading cause of cancer-related deaths for both 
men and women worldwide (1) and is a serious and growing 
health problem in China, with approximately 600,000 deaths 
each year. The cancer rate has been rising in China since the early 
1980s because of the increasing smoking population (2). Thoracic 
radiotherapy (RT) remains the standard and widely utilized treat-
ment modality for inoperable, locally advanced non-small cell 
lung cancer (LA-NSCLC).
Randomized studies have demonstrated that concurrent 
chemoradiotherapy (CCRT) yielded better survival rates than the 
sequential approach but with higher treatment toxicities (3, 4). 
Besides efficacy, treatment toxicity does influence the treatment 
of choice by oncologists and patients (3, 4). Comprehensive litera-
ture reviews have shown that toxicity profile is more favorable in 
low-dose CCRT, but low-dose CCRT has not been widely adapted 
worldwide (5). In addition, in the era of CCRT, the chest tumor 
control rate has been disappointing, averaging less than 50% 
by radiographic criteria. Uncontrolled chest tumors (including 
both the primary and hilar/mediastinal lymph nodes) represent 
a major barrier to further therapeutic gain, as surviving cancer 
cells in residual chest tumors can seed distant metastases. In this 
context, the significance and the impact of chest local–regional 
tumor control for LA-NSCLC on survival outcome has been 
analyzed in 1,390 patients treated in 7 legacy Radiation Therapy 
Oncology Group (RTOG) trials by CCRT for LA-NSCLC (6). 
This analysis revealed that the chest local–regional tumor con-
trol rate at 3 years was 38% at best and only 14% using a more 
strict definition (7). This analysis did find a powerful association 
between chest local–regional tumor control and overall survival 
(OS), which was statistically significant (p = 0.0001). Such finding 
highlights the importance of chest tumor control on the survival 
outcome of LA-NSCLC.
Optimal CCRT in maximizing chest tumor control and mini-
mizing toxicities remains to be defined. Taxane-based CCRT has 
been favored for the treatment of LA-NSCLC by many oncologists 
worldwide. Taxanes are known to have antiangiogenic effects on 
tumor vasculature (8, 9). These are also cell cycle-specific chemo-
therapeutic agents that can cause cytokinetic stabilization of the 
spindle microtubules leading to apoptotic cell death (10, 11). The 
cell cycle effect of paclitaxel on the arrest in the G2/M phase, the 
most radiosensitive phase, makes it an ideal radiation sensitizer 
to enhance RT effects (12). In the U.S., weekly paclitaxel-based 
CCRT has been published in many phase 1, 2, and 3 clinical tri-
als for CCRT, and has been shown to be better tolerated than 
cisplatin-based CCRT (13, 14).
Weekly low-dose carboplatin and paclitaxel with concurrent 
radiation combination is a widely accepted standard in the 
U.S. and Europe for LA-NSCLC. Despite common practice, 
the optimal dose-schedule of paclitaxel for CCRT treatment of 
LA-NSCLC remains to be defined. Previously, a phase 1 and 2 
clinical study was conducted using pulsed, low-dose paclitaxel 
CCRT for LA-NSCLC (15, 16). Based on preclinical investiga-
tions, it was hypothesized that a regimen of schedule-dependent, 
pulsed, low-dose paclitaxel CCRT could yield effective radiosen-
sitization to improve chest tumor control. This clinical trial has 
reported promising tumor response rates and a high rate of infield 
tumor control with low toxicities (15–17). We also conducted a 
phase 1 clinical study testing this hypothesis-based study design 
in China (18). Following up the phase 1 study, we conducted a 
multicenter randomized phase 3 study comparing two low-dose 
sensitizing paclitaxel schedules of CCRT for LA-NSCLC. We 
hypothesized that a schedule-dependent, pulsed low-dose pacli-
taxel (15  mg/m2, three times per week) CCRT regimen would 
yield better recurrence-free survival (RFS) than the commonly 
applied weekly paclitaxel (45 mg/m2) radiation regimen due to 
more effective radiosensitization.
METHODS
Patient Eligibility
This multi-institutional clinical study is registered with the 
Chinese Clinical Trial Registry (ChiCTR-TRC-10000786) and 
was conducted under the approved clinical protocol of the 
institutional review board at Beijing Cancer Hospital (RCOG-
0701) and each participating hospital. At the time of this study, 
separate institutional review board reviews were not necessary 
for investigators from other hospitals to participate in the study. 
All patients gave written informed consent to study participation. 
Patients with histologically or cytologically confirmed inoperable 
stage IIIA or IIIB NSCLC were eligible. In our region in China, 
most patients with LA-NSCLC would have completed 2–4 cycles 
of chemotherapy before referral for chest RT. In consideration of 
the logistics of patient enrollment, patients who had completed 
2–4 cycles of induction chemotherapy within 4–8 weeks prior to 
the referral for chest RT were eligible.
Patients needed to have at least one bidimensionally or uni-
dimensionally measurable tumor <8 cm in size on CT imaging. 
Additional eligibility criteria included patient age of 18–75 years, 
<10% weight loss within 6 months, ECOG performance status 
0–1, leukocyte count ≥4,000/μL, neutrophil count ≥1,500/μL, 
platelet ≥100,000/μL, hemoglobin ≥10  g/dL, creatinine ≤1.5 
upper normal limit, total bilirubin ≤1.5 upper normal limit, 
AST and ALT ≤2.5 upper normal limit, alkaline phosphatase ≤5 
upper normal limit, and FEV1 >50% predicted. Exclusion criteria 
included pregnancy, significant cardiac disease, uncontrolled 
diabetes, second primary tumor other than non-melanoma skin 
cancer or in situ cervical carcinoma, serious infections, uncon-
trollable psychoses, hypersensitivity to paclitaxel, or participation 
in another clinical trial. Clinical evaluation included weight, 
performance status, blood tests, pulmonary function test, and 
ECG. Radiographic staging included chest X-ray, ultrasound of 
upper abdomen and supraclavicular lymph nodes, computed 
tomography of chest, magnetic resonance imaging or computed 
tomography of the brain, and bone scan. Some patients had FDG-
PET scans, but this was not a required test per the study protocol.
Treatment Schema
The allowed induction chemotherapy included cisplatin-
containing dublets: vinorelbine/cisplatin, gemcitabine/cisplatin, 
paclitaxel/cisplatin, docetaxel/cisplatin, or pemetrexed/cisplatin. 
Enrolled patients were randomly assigned to one of the two 
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treatment arms using the published maximum tolerated dose 
(18). CCRT was initiated 4–8 weeks after completion of induc-
tion chemotherapy. Arm 1 received CCRT with three-times 
weekly paclitaxel (15 mg/m2, three times per week on Monday, 
Wednesday, and Friday, with the cumulative total of 270 mg/m2 
in 6 weeks) and concurrent RT. Arm 2 received CCRT with the 
weekly paclitaxel (45 mg/m2, once/week, to the cumulative total 
270  mg/m2 in 6  weeks). 3D-conformal chest RT or intensity-
modulated RT were allowed. For Arm 1, daily RT was delivered 
at least 4 hours after paclitaxel infusion on Monday, Wednesday, 
and Friday to allow for cell cycle progression to the G2/M phase 
(15). For Arm 2, there was no stipulation of the timing of daily 
RT, which is common practice. All patients received standard pre-
medication (dexamethasone, diphenhydramine hydrochloride, 
and cimetidine) before paclitaxel infusion to reduce the risk of 
hypersensitivity.
Treatment Dose Modifications
Chemotherapy was discontinued if the granulocyte count was 
<0.5 × 103/mL and/or the platelet count was <25 × 103/mL and 
severe hypersensitivity occurred. Chemotherapy was delayed 
when the granulocyte count was <1.5  ×  103/mL and/or the 
platelet count <75 × 103/mL on the day of chemotherapy. If the 
granulocyte counts remained 0.5–1.5 ×  103/mL or the platelet 
counts remained 25–75 × 103/mL for more than 1 week, chemo-
therapy was discontinued.
radiotherapy
Radiotherapy treatment planning utilized CT simulations. Gross 
target volume (GTV) included the primary lesion and involved 
lymph nodes (1 cm or larger). Clinical target volume (CTV) was 
defined as the GTV plus a 0.6 or 0.8 cm margin, and the planning 
target volume (PTV) was defined as the CTV plus a 1–1.5 cm 
margin for setup uncertainty and respiratory motion. Regional 
lymph nodes were not electively irradiated. All patients received 
the prescribed dose (60–70  Gy/30–35 fractions/6–7  weeks) to 
95% of the PTV. Dose limitation for organ-at-risk was defined: 
lung V20 < 30%, esophagus V55 < 50%, heart V40 < 40%, and 
<40 Gy for maximum spinal cord dose.
assessment of Efficacy and Safety
The primary endpoint of the study was response rate assessed 
by RECIST criteria (19). The secondary endpoints were RFS and 
treatment-related toxicities of the two treatment arms. Toxicities 
were evaluated weekly during CCRT and follow-up visits. 
Follow-up evaluation included history and physical examina-
tions, CT scans of the chest, and blood tests 1 month post-CCRT 
and every 3  months thereafter. Local–regional responses to 
therapy were determined from the chest CT 1 month after the 
end of CCRT. Toxicity was monitored per Common Terminology 
Criteria for Adverse Events version 3.0 (20).
Sample Size Estimate
Based on a two-sided Fisher’s exact test with a targeted significance 
level of 5%, sample sizes of 60 in each treatment group would 
achieve 76% power to detect a significant difference of 25% in 
response rates between the two arms if the response rates in Arm 
1 and in Arm 2 were 75 and 50%, respectively. For the primary 
objective of comparing response rates between treatment arms, 
we planned to screen 134 (67 in each arm) and allow a 10% drop 
out rate to result in sufficient cases of 60 in each arm for the 
comparison of the primary endpoint.
randomization
In this study, we used the method of random number table, which 
belongs to the simple randomization and grouping the patients. 
We selected any number from the random number table and got 
next number in the same direction order for each patient. Each 
random number was divided by the number of groups (two in this 
study), then we grouped the patients according to the remainder. 
If the remainder was 1, the patient was enrolled into Group A; 
if the remainder was 0, the patient was enrolled into Group B. 
This method was much more effective, but the disadvantage was 
that the imbalance of results might exist. Guangying Zhu and 
statistician Yannan Yuan decided the method of randomization, 
randomly chose the first number from the random number 
table, and decided the right as the direction order. Anhui Shi 
and Hongmei Lin carried out the randomization and grouping, 
and participating physicians in the study were responsible for the 
enrollment and intervention of participants. This study was not 
blinded, as the treatment schema of each arm was self-evident of 
the randomized arms.
Statistical analysis
Clinical data were collected by the investigators of the par-
ticipating hospitals and centrally collected by Hongmei Lin and 
Yannan Yuan. RFS and OS were defined from the start time of 
any cancer treatment (first cycle of induction chemotherapy) to 
last follow-up after CCRT, or death due to any cause for OS, and 
any recurrence/progression (local, regional, and distant) for RFS. 
The distribution of OS and RFS were estimated using Kaplan and 
Meier’s method. They were compared between arms using a two-
sided log-rank test. Hazard ratios (HRs) and their 95% confidence 
intervals (CI) were constructed using Cox’s proportional hazard 
model. The comparison of response rates, patterns of failure, and 
the incidences of toxicities were analyzed using Fisher’s exact 
test and analysis of variance. Results were considered statistically 
significant at the 5% level (p < 0.05).
rESUlTS
Patient Characteristics
From March 2006 to February 2013, 134 patients were enrolled 
as planned. Random number table randomization resulted in 74 
patients in Group A for Arm 1 and 60 patients in Group B for 
Arm 2. Among Arm 1 patients, three patients went off the study 
(two for subsequent refusal and one for pulmonary infection 
before protocol treatment). Among Arm 2 patients, one patient 
went off the study because of refusal. The final number of cases 
for statistical analysis was 130, with 71 in Arm 1 and 59 in Arm 2 
(Figure 1). Despite some imbalance in each arm from randomi-
zation, the baseline patient and disease-related characteristics of 
TablE 1 | Comparison of baseline characteristics of patients who 
completed protocol treatments.
no. of patients p-Value
arm 1 (n = 71) arm 2 (n = 59)
Characteristics
age (years)
Median 59 56 0.540
Range 22–75 36–75
Sex
Male 57 (80%) 50 (85%) 0.507
Female 14 (20%) 9 (15%)
Ethnicity
Han 70 (99%) 58 (98%) 0.745
Other 1 (1%) 1 (2%)
Performance status
0 43 (61%) 42 (71%) 0.205
1 28 (39%) 17 (29%)
Histology
Squamous 42 (59%) 41 (69%) 0.123
Adenocarcinoma 23 (32%) 17 (29%)
Large-cell 4 (6%) 0
Adenosquamous 2 (3%) 1 (2%)
Stage
IIIA 25 (35%) 16 (27%) 0.323
IIIB 46 (65%) 43 (73%)
Weight loss
≤5% 63 (89%) 48 (81%) 0.236
>5% 8 (11%) 11 (19%)
FigUrE 1 | Consort diagram of patient randomization and treatments.
4
Lin et al. Low-Dose Paclitaxel Chemoradiotherapy for NSCLC
Frontiers in Oncology | www.frontiersin.org December 2016 | Volume 6 | Article 260
the two arms were not significantly different (Table 1). This study 
did not do blinding as a result of the study design.
rFS and OS
Data analyses were collected from patients receiving protocol 
treatments (71 in Arm 1 and 59 in Arm 2). Median follow-up was 
23.4 months (range 7.4–85.2). Figure 2 shows Kaplan–Meier RFS 
comparison of the two arms. RFS was significantly better in Arm 
1 than in Arm 2 [p = 0.005, HR 1.87 (95% CI 1.20, 2.90)]. The 
median RFS was estimated as 14.6 months (11.1–19.5) in Arm 1 
vs. 9.4 months (8.4–13.3) in Arm 2. OS was not significantly dif-
ferent between arms [p = 0.91, HR 0.97 (95% CI 0.55, 1.70)] with 
a median 32.6  months (23.1–46.8) in Arm 1 and 31.3  months 
(24.7–Inf.) in Arm 2 (Figure 3).
Tumor response and Patterns of Failure
The total response rate for Arm 1 was significantly higher (83.1%) 
than that of Arm 2 (54.2%) (p = 0.001) (Table 2). The pattern of 
failure is as follows: local failure in the radiation port 11 (28.9%) 
in Arm 1 vs. 18 (42.9%) in Arm 2 (p = 0.08); chest failure, i.e., 
new lesions outside of radiation port 7 (18.4%) in Arm 1 vs. 8 
(19.0%) in Arm 2 (p = 0.22); and distant failure 20 (52.6%) in 
Arm 1 vs. 16 (38.1%) in Arm 2 (p = 0.08). The differences in the 
patterns of failure between the two arms were not statistically 
significant.
Toxicities and Safety
The observed toxicity data were collected for the two arms. 
Four treatment-related deaths were reported within 9  days of 
initiation of the study: one in Arm 1 and three in Arm 2. In 
Arm 1, the patient died of possible radiation pneumonitis with 
a complicated infection (Pneumocystis carinii infection, PCP). 
In Arm 2, two patients died of possible radiation pneumonitis 
with complicated infection and one died of heart failure and low 
sodium chloride.
Non-hematological toxicities during the CCRT phase for 
Arms 1 and 2 are listed in Table 3. None of the non-hematologic 
toxicities were statistically different between the two arms. Grade 
3 or 4 hematologic toxicities are shown in Table  4. In Arm 1, 
3 patients developed Grade 3 or 4 leukopenia vs. 15 patients in 
Arm 2 (p < 0.001). None of the patients developed Grade 3 or 
4 neutropenia in Arm 1 in comparison to 10 patients in Arm 2 
(p < 0.001).
DiSCUSSiOn
Low-dose chemotherapy CCRT for LA-NSCLC has previ-
ously shown promising results with low toxicities by different 
investigators (15–17, 21–23). Among these, the best known 
is the randomized phase 3 study by Radiotherapy and Lung 
Cancer Cooperative Groups of the European Organization 
for Research and Treatment of Cancer, which compared very 
low-dose (6 mg/m2) daily cisplatin CCRT vs. weekly cisplatin 
(30 mg/m2) CCRT vs. RT alone for LA-NSCLC (21). Results 
demonstrated better survival of patients receiving daily low-
dose cisplatin and RT than patients who received RT alone or 
weekly cisplatin. Such low doses of daily cisplatin in this con-
text were thought to be the radiosensitizing effect of low-dose 
cisplatin in improving RT chest tumor control, which resulted 
in better survival while avoiding the toxicities of high-dose 
chemotherapy.
FigUrE 2 | recurrence-free survival compared between the two arms using Kaplan–Meier analyses. Group A represents Arm 1 (paclitaxel 15 mg/m2, 
three times per week), and Group B represents Arm 2 (paclitaxel 45 mg/m2 per week).
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However, low-dose CCRT for LA-NSCLC has not been 
widely adapted, while poor chest tumor control of LA-NSCLC 
remains a major challenge for oncologists. Several single institu-
tion phase 1 and 2 studies have attempted RT dose-escalation to 
74  Gy to improve chest tumor control and showed promising 
chest tumor control and survival (24–27). However, results of 
a phase 3 study (RTOG 0617) testing RT dose-escalation to 
74 Gy vs. standard 60 Gy was disappointing (28). The median 
OS was 28.7  months (95% CI 24.1–36.9) for the 60  Gy arm 
and 20.3 months (17.7–25.0) for the high-dose 74 Gy arm (HR 
1.38, 95% CI 1.09–1.76; p =  0.004). The exact reasons for the 
worse survival outcome in the 74 Gy arm remain to be eluci-
dated. Nevertheless, the outcome of RTOG 0617 highlights the 
unresolved challenge in improving chest tumor control, and the 
need for novel strategies to enhance RT efficacy in the combined 
modality treatment of LA-NSCLC.
Pulsed low-dose paclitaxel was previously reported to be 
an effective radiosensitizing strategy (15–17). Chen et  al. (17) 
reported that the kinetics of tumor shrinkage after pulsed low-
dose paclitaxel CCRT were different from the standard conven-
tional CCRT schedules, in that rapid tumor shrinkage occurred 
within 1 month after completion of CCRT, which is in contrast 
to the gradual tumor regression over a 5- to 6-month interval 
commonly observed (29). In addition to the rapid initial tumor 
responses, the infield (radiation port) tumor control was above 
97% at 3  years. The exact mechanism of such rapid and effec-
tive tumor response and durable infield tumor control of pulsed 
low-dose paclitaxel CCRT is unknown, but one can theoretically 
attribute to the combined effects of paclitaxel G2/M cell cycle 
effect (9), its apoptotic effect (10, 11), tumor reoxygenation effect 
(30), and/or the antiangiogenic effect of low-dose chemotherapy 
delivered through metronomic dose schedules (31, 32). In the 
same context, we acknowledge that because the tumor response 
of standard treatment schedules is a gradual process, choosing 
any time point after CCRT to assess response rate is somewhat 
arbitrary and may be in favor of Arm 1. We chose the 1-month 
time point with the understanding of this issue. However, the RFS 
analyzed by the Kaplan–Meier method provided complementary 
information that was clinically more important than response 
rates, and Kaplan–Meier analysis would have accounted for the 
changes over a long period of time for both local tumor control 
and distant tumor control.
Our study reported significantly better tumor response 
rate, better RFS, and lower rates of Grade 3 and 4 leukopenia 
TablE 2 | Tumor response.
response rate arm 1 
(n = 71)
% arm 2 
(n = 59)
% p-Value
no. of 
patients
no. of 
patients
Complete response 7 9.86 2 3.39
Partial response 52 73.24 30 50.85
Stable disease 8 11.27 23 38.98
Progression 4 5.63 4 6.78
Total response (CR + PR) 59 83.1 32 54.2 0.001
Arm1, 15 mg/m2, three times a week; Arm 2, 45 mg/m2, once a week.
FigUrE 3 | Overall survival compared between the two arms using Kaplan–Meier analyses. Group A represents Arm 1 (paclitaxel 15 mg/m2, three times 
per week), and Group B represents Arm 2 (paclitaxel 45 mg/m2 per week).
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and neutropenia in the pulsed low-dose paclitaxel arm. The 
low rate of toxicities is consistent with the literature review on 
low-dose CCRT (5). We neither observed a significant difference 
in the patterns of failure of the two arms nor did we observe a 
significant difference in esophagitis or pneumonitis or other 
radiation-related acute side effects in the two arms. One may 
wonder why the better RFS in Arm 1 did not result in better OS, 
and if treatment-related toxicities may contribute to the lack of 
trend toward improving OS of Arm 1. We reviewed the Grade 
5 toxicities of both arms, and there was only one Grade 5 lung 
toxicity in Arm 1 and two in Arm 2, thus Grade 5 toxicity did 
not contribute to the lack of OS benefit. Much larger sample sizes 
would have been necessary to reach any statistical power to detect 
the difference in OS.
We acknowledge that there are potential weaknesses of our 
study. The random number method is an assignment process in 
which all patients were assigned to either Group A or B completely 
at random, without monitoring the size of the groups. Our study 
design had planned to screen 134 patients with 67 randomized 
in each arm and to allow a 10% drop out rate. This design would 
have resulted in an estimated 60 patients in each arm for the final 
data analyses. Due to the method of random number table for the 
assignment of randomization, our study enrolled 74 patients in 
Arm 1 and 60 patients in Arm 2. In retrospect, we acknowledge 
that it would have been better to have a built-in process to bal-
ance assignments between the arms. However, despite the minor 
imbalance in randomization, the study resulted in sufficient 
number of cases in each arm for the study endpoint analyses 
(71 in Arm 1 and 59 in Arm 2), and there was no statistically 
significant imbalance of patient characteristics in the two arms 
(Table 2).
We chose to analyze our data based on patients completing the 
treatment regimen in the assigned arm instead of basing on the 
TablE 4 | Hematological toxicities: ≥grade 3.
arms leucopenia neutropenia anemia Thrombopenia
grades g-3 g-4 g-3 g-4 g-3 g-4 g-3 g-4
1 (n = 71) 3 0 0 0 1 0 0 0
2 (n = 59) 14 1 8 2 2 0 2 1
p-Value <0.001 <0.001 0.43 0.48
TablE 3 | non-hematological toxicities.
Toxicities arm 1 (n = 71)  
vs. arm 2  
(n = 59)
grades (no. of patients) p-Value
g-1 g-2 g-3 g-4 g-5
Weight loss 1 7 1 0 0 0 0.32
2 10 1 0 0 0
Fatigue 1 22 2 0 0 0 0.13
2 14 7 0 0 0
Fever 1 23 10 0 0 0 0.97
2 18 8 0 0 0
Nausea 1 8 10 0 0 0 0.34
2 3 11 1 0 0
Vomiting 1 1 1 0 0 0 0.55
2 3 1 0 0 0
Cough 1 28 9 0 0 0 0.47
2 24 5 2 0 0
Dyspnea 1 11 5 1 0 0 0.84
2 6 4 1 0 0
Esophagitis 1 15 21 3 0 0 0.11
2 4 21 5 0 0
Pneumonitis 1 1 8 13 0 1 0.52
2 3 7 6 0 2
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intention to treat (ITT). We think that final analyses of patients 
completing the treatment regimen in each arm have served the 
goal of our study better. The benefit of analysis based on ITT is 
to avoid effects from dropout and/or crossover, which may break 
the random assignment to the treatment groups in a study. Our 
study had very low dropout rates in both arms and did not allow 
for crossover, thus basing ITT for the analysis would not have 
made much difference.
Current practice standard is CCRT upfront for patients with 
good performance status, while induction chemotherapy fol-
lowed by RT has been reserved for patients who cannot tolerate 
CCRT (33). A randomized phase 3 study did not demonstrate 
any benefit of adding induction chemotherapy to CCRT (34), 
and there is the lack of prior studies on induction chemo-
therapy followed by very low-dose CCRT for LA-NSCLC. We 
acknowledge that our study design is different from the current 
standard CCRT treatment regimens for LA-NSCLC due to 
logistical reasons and pattern of referrals in our region. Patients 
enrolled in our study had received 2–4 cycles of induction 
chemotherapy prior to enrollment. Because our primary goal 
was to assess low-dose chemotherapy in sensitizing chest RT 
to improve chest tumor responses, we designed the enrollment 
of patients to include the 2–4 cycles of cisplatin-based induc-
tion chemotherapy upfront, with the assumption that as long 
as all patients had received 2–4 cycles of cisplatin containing 
induction chemotherapy, the potential systemic effect on distant 
micrometastasis from induction chemotherapy would balance 
both arms. We acknowledge that it would have been helpful if 
the study were designed to include the induction chemotherapy 
followed by CCRT and had assessed tumor response to induc-
tion chemotherapy, but this was not feasible due to local practice 
and referral pattern.
In conclusion, our study showed that three times weekly 
paclitaxel (15 mg/m2) yielded better RFS and tumor responses, 
with lower hematologic toxicity than the weekly paclitaxel 
(45  mg/m2) schedule for CCRT in patients with LA-NSCLC 
who have received 2–4 cycles of induction chemotherapy. 
Based on this study, the survival of both arms was equivalent, 
but the low-dose arm experienced less toxicity. Whether low-
dose paclitaxel CCRT translates to a survival benefit needs to be 
tested in a larger randomized study. In an era when maintaining 
quality of life during cancer therapy is important to patients, 
a regimen with low toxicity and better tumor control will be 
appropriate for those who cannot tolerate intense CCRT for 
LA-NSCLC.
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